precisionmedicineonline9h
Spur Therapeutics, FDA Align on Phase III Plans for Gaucher Disease Gene Therapy
The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...
BioSpace1d
GH’s Inhaled Psychedelic Succeeds in Mid-Stage Depression Trial
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...